The hypervariable region 3 (V3) within the disulfide-bridged loop of the envelope protein of the human immunodeficiency virus type 1 (HIV-1) contains an amino acid sequence that was defined as a principal neutralizing determinant (PND). A 19-amino acid residue consensus sequence (designated V3C) predicted from the PND sequences of 245 isolates as well as a sequence from the PND of the WMJ2 HIV-1 isolate (designated V3M) were expressed on the variable region of murine-human immunoglobulin (Ig) chimeras that were designated Ig-V3C and Ig-V3M, respectively. The HIV-1 sequences on the Ig chimeras preserved their antigenicity and interacted with antibodies specific for peptides encompassing the V3C and V3M sequences. In baboons, Ig-V3C and Ig-V3M induced antibodies that bound V3C and V3M peptides as well as the glycoprotein gpl20 envelope protein of HIV-1 MN isolate. In addition, the baboons' antisera were able to prevent infection of CD4 SupT1 susceptible T cells by HIV-1 MN. Finally, Ig-V3M chimeras were able to stimulate in vitro production of antibodies specific for the HIV-1 envelopederived peptides by lymphocytes from HIV-i-infected human subjects.
A wealth of information on the human immunodeficiency virus (HIV) has been gathered since its discovery 12 years ago (1) . To date, vaccines or therapeutic agents able to prevent the spread of HIV or to block the irreversible progress of HIV infection to fatal disease are not available. The development of a safe and efficient vaccine against this virus represents a major task to control its spreading. To this aim various vaccine-development approaches were undertaken. These include use of inactivated whole virus (2, 3) , natural and recombinant envelope protein (4-6), viral and bacterial vectors expressing HIV sequences (7) (8) (9) (10) (11) , synthetic peptides (12) , anti-idiotypic antibodies (13) , antigenized immunoglobulin (Ig) expressing a CD4 epitope (14) , and naked DNA (15) .
In previous studies we have shown that viral T-cell epitopes expressed on the heavy chain variable (VH) region of Ig molecules are highly immunogenic at the level of both CD4+ and CD8+ T cells (16) (17) (18) . The advantage of this approach is that Ig molecules are safe as antigen delivery systems and have long half-lives when compared with synthetic peptides.
In this study, sequences of the principal neutralizing determinant (PND) from the hypervariable region 3 (V3) loop of HIV type 1 (HIV-1) envelope protein (19) were expressed on mouse-human Ig molecules, and the resulting Ig-V3 chimeras were tested with respect to induction of anti-HIV antibody response either in baboons or by in vitro stimulation of human lymphocytes. The results indicate that the Ig-peptide chimeras were able to induce in baboons anti-peptide antibodies that bind the envelope protein and neutralize HIV-1 virus. They also stimulate human lymphocytes for production of antibodies specific for HIV-1-derived peptides in vitro.
MATERIALS AND METHODS
Genetic Engineering of Antigenized Igs. Polymerase chain reaction (PCR) mutagenesis similar to those previously described to generate VH genes carrying influenza A virus epitopes (16, 17) was used to insert HIV-1 V3 loop peptides in Ig. Briefly, a pUC19 plasmid harboring the 5.5-kb EcoRI fragment carrying the VH gene of the murine anti-arsonate antibody, 91A3 (20) , was used as template DNA in two PCRs to delete the diversity (D) segment of the complementaritydetermining region 3 (CDR3) loop and instead insert nucleotide sequences encoding the selected HIV peptides. Two chimeric VH genes were generated. The first carries sequences encoding a 19-amino-acid-residue consensus peptide (designated V3C peptide; see the sequence below under Antigens) from the V3 loop of HIV-1 envelope protein (21) , and the second harbors sequence also encoding a 19-residue peptide (designated V3M peptide) from the V3 loop of the WMJ2 HIV-1 isolate (21) . These chimeric VH genes as well as the wild-type 91A3 VH gene were subcloned into the EcoRI site upstream of the exons encoding a human Ig yl heavy chain constant (C) region within the plasmid pSV2AHgptDNSVH-hCyl (22) from which the EcoRI dansyl (dns)-conjugated VH gene was cut out. Thus, three constructs were generated: pSV2AHgpt91A3VH-V3C-hC,yl, which carries nucleotide sequence encoding the consensus V3C peptide in place of the D segment; pSV2AHgpt91A3VH-V3M-hC-yl, which carries nucleotide sequence encoding the V3M peptide; and pSV2AHgpt91A3VH-D-hC,yl, which carries the D segment of parental 91A3VH gene. The sequences encoding the HIV peptide and surrounding regions were determined and confirm their insertion in the correct frame (not shown).
To express these chimeric murine 91A3 VH-human Cy, heavy chain genes with a mouse-human chimeric K light chain gene, we proceeded as follows. The 8-kb BamHI fragment encoding the entire murine 91A3 K light chain gene (23) was Abbreviations: BSA, bovine serum albumin; HIV-1, human immunodeficiency virus type 1; PBMC, peripheral blood mononuclear cells; PND, principal neutralizing determinant; V, variable; VH, heavy chain V region of immunoglobulin; V3, hypervariable region 3 of the envelope protein of HIV-1; Ig-V3 chimeras, Ig carrying amino acid residues from the V3 loop of HIV; TT, tetanus toxoid; dns, dansyl; C, constant; D, diversity. §To whom reprint requests should be addressed.
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subcloned into the BamHI site of pUC19 plasmid. Subsequently, a HindIII fragment encompassing the K light chain promoter and the VTK region coding sequences was cut out from this plasmid and subcloned into the HindIII site of pSV184AHneoDNSVK-hCK upstream of the gene encoding a human K light chain C region (CK) from which the dnsconjugated VK (dnsVK) had been excised (24) . This plasmid, which will encode a murine 91A3 VK-human CK light chain, is designated pSV184AHneo91A3VK-hCK.
Gene cloning, plasmid purification, hybridization, and DNA fragment separation and elution from agarose gels were carried out as described (16) Research and were housed in gang cages for the duration of the study. Male baboons between the ages of 10 and 13 years were used. New Zealand White rabbits (3 kg) were used for the production of anti-peptide antibodies.
Antigens. The synthetic peptide V3C (Arg-Lys-Ser-Ile-HisIle-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr-Thr-Gly-Glu-Ile-Ile) corresponds to a consensus sequence from the PND of the V3 disulfide-bridged loop of HIV-1 envelope (19) . This sequence was predicted from the comparison of PND sequences of 245 isolates (21) . V3M (Arg-Arg-Ser-Leu-Ser-Ile-Gly-Pro-GlyArg-Ala-Phe-Arg-Thr-Arg-Glu-Ile-Ile-Gly) corresponds to amino acid residues of the PND of WMJ2 HIV-1 isolate at the same positions as in the consensus sequence (21) . The peptide HIV-(519-535) (Ala-Val-Gly-Ile-Gly-Ala-Leu-Phe-Leu-GlyPhe-Leu-Gly-Ala-Ala-Gly-Ser), corresponding to amino acid residues 519-535 of the envelope of HIV-1 IIIB isolate, was also used. Peptide synthesis, purification by reverse phase (RP)-HPLC, and conjugation to keyhole limpet hemocyanin and bovine serum albumin (BSA) were carried out by previously described techniques (25) . Viral lysates from purified HIV-1 IIIB isolate were purchased from Organon TeknikaCappel, and lysates from cells infected with the MN isolate were provided to us by A. Painter and B. Honen (New York University).
Production of HIV Peptide-Specific Antibodies. Antipeptide antibodies were prepared in New Zealand White rabbits by immunization with peptide-keyhole limpet hemocyanin conjugates as described (25) . Anti-peptide antibodies were purified from serum on peptide-BSA-conjugated Sepharose columns, and the antibodies were eluted with 0. Detection of Anti-V3 Peptide Antibodies in Baboon Serum and in Supernatant from Human Lymphocyte Culture. Microtiter plates were coated overnight with peptide-BSA conjugate (100 ,ul at 2 ,ug of peptide per ml of PBS) or BSA (100 Al at 2 ,ug/ml). The plates were then washed and blocked with goat serum containing 5% BSA. After 1 hr, the plates were washed and incubated with various dilutions of test samples for 2 hr at room temperature. Bound baboon or human antibodies were revealed with 1251-labeled goat anti-human IgG antibodies.
Radioimmunoprecipitation Assay (RIPA). The RIPA assay was performed as described (25) . Briefly, mature virus lysates were labeled with 1251 and precleared on Pansorbin cells (Calbiochem), and 2 x 106 cpm was incubated overnight at 4°C with 20 ,lI of baboon serum, 10 ,l of rabbit serum, or 2 ,ul of human serum. Samples were then warmed for 10 min at 37°C, and complexes were removed with Pansorbin cells. After heat denaturation, the proteins were separated on a 10% acrylamide gel. HIV-1 Neutralization Assay. Baboon sera were tested for HIV-1 MN and IIIB neutralizing activity by using two in vitro neutralization assays that have been described (26, 27) . The first assay utilized HIV-1 ITIB isolate and examined viral cytotoxicity. Briefly, 50 ,ul of the heat-inactivated test sera diluted 1:50 to 1:400 were preincubated with 100 TCID50 (50% tissue culture infectious doses) for 1 hr at 37°C. This mixture was then added to susceptible SupTl cells and incubated for 8 days. Subsequently, the vital dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) was added for 4 hr. The cultures were inactivated and the optical density at 570 nm was determined. Incorporation of MTT indicated viable cells, and the HIV-1 IIIB-induced cytotoxicity was inhibited.
The second assay utilized HIV-1 MN isolate and measures p24 production in the supernatant. This assay is used because the MN isolate is not cytotoxic for SupTl cells. The assay was carried out as above except that at day 8, p24 was measured in the tissue culture supernatant. The level of HIV-1 p24 in the supernatant was determined by using a Coulter ELISA kit according to the manufacturer's specifications. The percent neutralization was calculated as described (26, 27 Ig-W-TT were added, and the cultures were incubated at 37°C in an atmosphere containing 7% CO2 for 7-10 days. The supernatants were then assayed for the presence of anti-V3M and anti-V3C antibodies as above.
RESULTS
Antigenicity of HIV-1 Peptides Expressed on Ig Chimeras. As indicated in Fig. 1 Upper, three different Ig molecules were generated in which the heavy and light chain V regions are of the murine 91A3 anti-arsonate antibody, while the C regions are derived from human -yl and K chains. Ig-V3C carries V3C peptide, and Ig-V3M carries V3M peptide in place of the D segment. Ig-W is a control molecule encoded by unmodified genes and therefore carries the parental D segment. Chimeric Igs were affinity-purified on an anti-human K chain mAb column and were assayed for chain assembly and HIV peptide expression by radioimmunoassay. When Ig-V3C, Ig-V3M, and Ig-W are captured by an anti-human K chain mAb, they bind 125I-labeled goat anti-human Fczy antibodies, indicating that the replacement of the D segment with HIV peptides did not alter chain assembly or the folding of the molecule (Fig. 1 Lower a). The control molecule Ig-HA, which is entirely murine Ig, did not bind to anti-human antibodies. Furthermore, Ig-V3C and Ig-V3M, but not Ig-W or Ig-HA, bind rabbit antibodies specific for either V3C (Fig. 1 Lowerb) or V3M ( Fig.  1 Lower c) peptides. These results indicate that V3C and V3M peptides on Ig-V3C and Ig-V3M, respectively, are exposed and preserved their antigenicity.
Induction of HIV-1-Neutralizing Antibodies in Baboons Immunized with Chimeric Igs. Groups of baboons were immunized with Ig-V3C, Ig-V3M, or control Ig-W, and serum samples collected before and after immunization were tested for the presence of antibodies to V3C and V3M peptides and to an unrelated peptide corresponding to amino acid residues 519-535 of the HIV-1 IIIB isolate. The results of representative baboons are illustrated in Fig. 2 . Baboons that were immunized with either Ig-V3C or Ig-V3M produced antibodies to the V3 loop peptides, while those immunized with Ig-W did not. These antibodies are specific for V3 peptides since they did not bind the HIV-(519-535) peptide. While serum from the baboon immunized with Ig-V3M bound only V3M peptide, serum from the baboon immunized with Ig-V3C bound both V3M and V3C peptides. A significant level of antibodies was detectable at day 65 (14 days after the third immunization). However, higher antibody levels were obtained at day 164 (14 days after the fifth immunization). The results depicted in Fig.  3 indicate that anti-peptide antibodies from baboons immunized with either Ig-V3C or Ig-V3M bind a 120-kDa protein when incubated with MN virus lysates, as does the control human serum from HIV-1-infected individuals. A rabbit antiserum raised against HIV-(503-535) peptide (25) binds to the envelope protein of both MN and IIIB isolates, while the baboon serum did not bind to gpl20 of the IIIB isolate. No binding to either MN or IIIB proteins was obtained when the lysates were incubated with serum from a baboon immunized with Ig-W. These results indicate that immunization of baboons with Ig-V3C and Ig-V3M induces antibodies that bind native envelope protein of HIV-1.
Furthermore, baboon antibodies exhibited virus neutralization properties. As can be seen in Fig. 4 Production of anti-PND antibodies subsequent to immunization of baboons with Ig-V3C and Ig-V3M. Sera from baboons were immunized with the Ig chimeras indicated in c, and were assayed for binding to the V3C-BSA conjugate (a), the V3M-BSA conjugate (b), the HIV-(519-535)-BSA conjugate (c), and BSA (not shown) as described in text. The immunization and bleeding schedule was as follows: baboons were bled on day 1 and were immunized with 500 ,tg of an Ig-peptide chimera emulsified in Freund's incomplete adjuvant on day 15, and in alum on days 29 and 43. The animals were bled on days 65, 80, and 101. They were administered a booster containing 500 ,g of Ig-peptide chimeras in alum on days 122 and 150 and were bled on days 136, 164, and 178. The sera were tested at various dilutions (1:10, 1:100, and 1:1000), and the data shown were obtained with 1:100 serum dilution. Each dilution was tested in triplicate wells, and the indicated cpm represent the mean ± SD after deduction of background cpm obtained on plates coated with BSA. isolate but not the IIIB isolate, while antiserum from a baboon immunized with Ig-W failed to neutralize either of the two isolates. Significant HIV-1 MN-neutralizing activity was detected in samples collected on days 101, 136, and 164 (14 days after the third, fourth, and fifth immunization, respectively) (not shown). The dose-effect relationship between neutralization activity and serum dilution indicates that neutralization is dependent upon the quantity of serum antibodies.
In Vitro Production of Antibodies Specific for HIV-1-Derived Peptides by Human Lymphocytes Stimulated with Ig-W chimeras were tested for HIV-1 MN (Left) and IIIB (Right) neutralizing activity as described in text. All bleeds from day 1 to day 178 were tested, and the data shown are those obtained with sera collected at day 164. The percent neutralization was calculated as described (26, 27) .
Ig-Peptide Chimeras. Since Ig-peptide chimeras carrying HIV-1 envelope-derived epitopes were able to induce HIV-1-neutralizing antibodies in baboons, we carried out in vitro experiments to determine whether human lymphocytes could similarly produce anti-HIV-1 antibodies subsequent to in vitro stimulation with the chimeras. In preliminary experiments, we tested serum from 20 HIV-1-infected asymptomatic patients for presence of antibodies specific for V3M and V3C peptides. Nine subjects had antibodies that bound to V3M and V3C peptides (not shown). Two of these individuals (CE and SLF) and one healthy subject (K) were selected for this study. PBMC from these individuals were incubated with Ig-peptide chimeras alone or coupled to TT, and supernatants were harvested at days 7 and 10 and were tested for the presence of anti-HIV-1 antibodies. Fig. 5 depicts the results of a representative experiment among two performed at 2-month intervals. PBMC from patients (CE and SLF) incubated for 10 days with either Ig-V3M-TT or Ig-V3M produced antibodies that bound to both V3M and V3C peptides (Fig. 5 a, b, d , and e). Lower antibody titers were obtained when the PBMC were incubated for only 7 days (not shown). No antibodies to V-161 peptide (negative control) could be detected in these supernatants (not shown).
The wild-type Ig-W did not induce antibodies to either V3C or V3M peptides (Fig. 5 c and f) . PBMC from a healthy subject (K) did not produce any detectable anti-HIV-1 antibodies (open circles in Fig. 5 ), indicating that the cells producing the HIV-1-specific antibodies in asymptomatic patients are memory cells that have previously been primed. Optimal antibody production required lower amounts of antigen when the a 9.8 dp X Binding to V3M peptide Ig-V3M 1g/m Ig-V3M-lT, jigml Fig. 6 ) play an important role in the shaping of antibody response to this PND.
More striking, Ig-peptide chimeras stimulated in vitro antibody response by human PBMC from HIV-1-infected patients. The response was higher when the PBMC were exposed to Ig chimeras that are coupled with TT. This suggests that TT-specific memory T cells induced by vaccination might provide help to V3M-stimulated B cells. This is supported by the findings that Ig-V3M-TT elicited a better antibody response than uncoupled Ig-V3M in two different HIV-1-infected patients.
The results indicate that Ig molecules expressing HIV-1 V3 loop peptides are able to induce virus-neutralizing antibodies in baboons and to stimulate the production of HIV-1-specific antibodies by human lymphocytes. It is still not clear whether the V3 loop of the envelope protein represents the best target for the development of HIV vaccine. However, the ability of Ig chimeras to induce antibody response in asymptomatic patients pleads for the potential for development of a new generation of therapeutic rather than prophylactic vaccines (28) . There is evidence indicating that vaccines can boost host-defense reactions in subjects infected with viruses or parasites (28) . (21) . A dash indicates amino acid identity, and an asterisk indicates a gap.
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